Summit Therapeutics PLC Total Liabilities
Summit Therapeutics PLC total liabilities. Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has total liabilities worth $122.20 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Summit Therapeutics PLC's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Summit Therapeutics PLC (2003–2025)
Total liabilities of Summit Therapeutics PLC from 2003 to 2025. This chart illustrates how Summit Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data.
Summit Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Summit Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Electric Power Corp
KO:015760
|
Korea | ₩206.38 Trillion |
|
QXO, Inc.
NYSE:QXO
|
USA | $6.50 Billion |
|
Penumbra Inc
NYSE:PEN
|
USA | $443.96 Million |
|
Formosa Chemicals & Fibre Corp
TW:1326
|
Taiwan | NT$169.86 Billion |
|
Sichuan Chuantou Energy Co Ltd
SHG:600674
|
China | CN¥22.59 Billion |
|
VERBUND AG ADR 1/5/O.N.
F:OEW
|
Germany | €7.28 Billion |
|
Akamai Technologies Inc
NASDAQ:AKAM
|
USA | $6.50 Billion |
|
China Galaxy Securities Co Ltd Class A
SHG:601881
|
China | CN¥707.95 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Summit Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SMMT current and non-current assets.
Liquidity & Leverage Metrics
Summit Therapeutics PLC Total Liabilities Ratios Explained
Summit Therapeutics PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Summit Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Summit Therapeutics PLC (2003–2025)
The table below shows the annual total liabilities of Summit Therapeutics PLC from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $68.52 Million | +83.17% |
| 2024-12-31 | $37.41 Million | -62.26% |
| 2023-12-31 | $99.12 Million | -77.38% |
| 2022-12-31 | $438.18 Million | +1864.49% |
| 2021-12-31 | $22.30 Million | +31.77% |
| 2020-12-31 | $16.93 Million | +18.03% |
| 2019-12-31 | $14.34 Million | -39.58% |
| 2018-12-31 | $23.74 Million | -61.96% |
| 2017-12-31 | $62.40 Million | +21.53% |
| 2016-12-31 | $51.35 Million | +814.38% |
| 2015-12-31 | $5.62 Million | -42.07% |
| 2014-12-31 | $9.69 Million | +132.02% |
| 2013-12-31 | $4.18 Million | +73.35% |
| 2012-12-31 | $2.41 Million | +3.02% |
| 2011-12-31 | $2.34 Million | +4.64% |
| 2010-12-31 | $2.24 Million | -56.61% |
| 2009-12-31 | $5.15 Million | -33.65% |
| 2008-12-31 | $7.77 Million | -49.24% |
| 2007-12-31 | $15.30 Million | +141.81% |
| 2006-12-31 | $6.33 Million | +153.93% |
| 2005-12-31 | $2.49 Million | +611.58% |
| 2004-12-31 | $350.21K | +9500.03% |
| 2003-12-31 | $3.65K | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more